xista science ventures’ Post

Great news from CatalYm: we have successfully completed an oversubscribed $150 million Series D #financing to advance our lead program #visugromab into randomized Phase 2b clinical trials. This investment will expand visugromab’s late-stage clinical development into earlier lines of treatment including checkpoint naïve and second-line refractory settings in select #SolidTumor indications. We extend a warm welcome to our new investors: Canaan, Bioqube Ventures, Omega Funds, Forbion Growth Fund and Gilde Healthcare Partners. Together with support from our participating existing investors JEITO, Brandon Capital, Novartis Venture Fund and Vesalius Biocapital III  the funding highlights the potential of visugromab to bring benefit to cancer patients and also values the novel approach of neutralizing GDF-15, a key resistance factor to anti-cancer therapies. Visugromab is a humanized monoclonal antibody targeting GDF-15, a key regulator of immune resistance to #cancer therapies. Our lead candidate has shown impressive results in a recent Phase 1/2a data update presented at #ASCO2024. The results demonstrated that the combination of visugromab and the PD-1 inhibitor nivolumab achieves deep and durable anti-tumor activity, including complete responses, in patients with anti-PD-(L)1 relapsed/refractory solid tumors. Along with the financing, Colleen Feriod Cuffaro, Partner at Canaan, Jon Edwards, Managing Partner at Bioqube Ventures, and Otello Stampacchia, Managing Director and Founder at Omega Funds, will join our Board of Directors, and Stefan Luzi, PhD, Partner at Gilde joins as an Observer. As we enter this next stage of corporate growth, we remain committed to our mission of breaking immunosuppressive barriers and establishing a new benchmark in cancer care. For more details on the financing, visit: https://lnkd.in/dBfHK4sU

#fundingalert 💼Company: NextPoint Therapeutics, Inc. 💰Funding: $42.5Million  ⚡Round: Series B 👥Investors: Catalio Capital Management, R. Jacob Vogelstein, MPM BioImpact, Leaps by Bayer, Sixty Degree Capital, Dana-Farber Cancer Institute NextPoint was founded by Ivan Cheung (CEO). The funds will be used to advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional #therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Their innovative approach integrates #foundational science with a defined #clinical biomarker strategy to deliver a new class of #monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Read more - https://lnkd.in/gx5rqfVC To share your startup story write us on - contact@startuprise.io #nextPoint #funding #startup

📢 CatalYm GmbH Raises $150m to Revolutionize Cancer Treatment 💰 German cancer specialist Catalym GmbH has raised $150m to finance proof-of-concept studies. 🔬 The aim is to demonstrate the efficacy, safety, and licensing potential of Visugromab plus Nivolumab in solid tumors. 💉 CatalYm GmbH plans to start Phase IIb trials in 2025. 🧪 Visugromab is a humanized monoclonal antibody designed to neutralize the tumor's own Growth Differentiation Factor-15 GDF-15. 💼 The financing round was led by Canaan Partners and Bioqube Ventures, and supported by other investors. #BioprocessUpdates #Catalym #funding #proofofconcept #Visugromab #Nivolumab #solidtumors #PhaseIIbtrials #monoclonalantibody #GDF15 #CanaanPartners #BioqubeVentures #investors #cancerspecialist #efficacy #safety #licensingpotential ▷ Read the full article here: 📎 https://lnkd.in/dsEJXwJg

🔬💡 Exciting News! 🌟 AltruBio Inc. Raises $225M in Series B Funding! 💰 Originally known as AbGenomics Holdings, the start-up initially focused on developing cancer drugs. But in 2020, it shifted course, swapped out its leadership and rebranded as AltruBio Inc.. The company raised $63 million in funding a year later, followed by a MASSIVE $225M oversubscribed Series B round earlier this week. The round comes amid a surge of industry interest in developers of immune disease drugs and the financing will help the company advance its ulcerative colitis candidate into mid-stage clinical trials. #AltruBio #Biotech #SeriesB #Innovation #UlcerativeColitis #TransformativeTherapies

#ICYMI Matthew Herper of STAT sat down with our CEO, Dr. J. Jean Cui, to learn more about her story and mission to develop effective therapeutics that tackle drug resistance. Discover how Dr. Cui and BlossomHill are applying human intelligence and creativity to drug design with the goal of extending survival and improving quality of life for #cancer patients. Read the full article here: https://bit.ly/49NRCLA     #precisionmedicine  

Congratulations to LightOx Ltd for raising £1.5m in investment to support their pioneering work on a groundbreaking treatment for early-stage oral cancer. This funding will help develop LXD191, an oral gel activated by light, targeting a serious pre-cancerous condition called oral epithelial dysplasia (OED). Current treatments are often invasive and painful, affecting 95% of patients and leaving 50% unable to return to work. The investment was made through our North East Innovation Fund, managed by Northstar Ventures UK, along with other investors led by GMC Life Sciences Fund by Praetura and made up of Bruntwood SciTech, Cheshire and Warrington Local Enterprise Partnership and Greater Manchester Combined Authority. Read more here: https://lnkd.in/gD6UmkQh North East Growth Hub The North East Combined Authority Invest South Tyneside South Tyneside Council #Innovation #CancerTreatment #InvestmentSuccess #Biotech #MedicalResearch

🚀 Exciting News! 🚀 We are thrilled to announce that our portfolio company, iOnctura, has closed a EUR 80 million Series B round! Led by Syncona Limited and the European Investment Council, this funding will drive the late-stage development of treatments for hard-to-treat cancers. Since our initial investment in 2019, iOnctura's team has delivered exceptional proof-of-concept data for its drug candidates, roginolisib and cambritaxestat, in rare tumors with high unmet needs. With this new financing, roginolisib will be tested in broader trials for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis, while cambritaxestat will advance for fibrotic cancers like metastatic pancreatic cancer. We are excited to welcome new investors and continue supporting iOnctura as it brings these critical treatments closer to patients in need. #Biotech #Investment #CancerTreatment #Pharma #Innovation #HealthTech #SeriesBRound #iOnctura #EuropeanInvestmentCouncil #Inkef

🚀 Mestastop Solutions, the biotech trailblazers, have secured Rs 4.5 crore ($500,000) in a Pre Series A round. This significant funding, led by 92 angels and Malpani Ventures, fuels its mission to transform cancer treatment by focusing on metastasis. In 2021, they already made waves with a Rs 2 crore seed funding round. Co-founded by Arnab Roy Chowdhury and Debabani Roy Chowdhury, Mestastop is pioneering a unique approach, combining wet lab biology and predictive analytics to identify metastasis properties. This breakthrough is set to revolutionize drug discovery and patient treatment in the fight against cancer. The global cost of cancer is expected to reach $25 trillion by 2050, with a $400 billion budget allocated for treatment and research by 2030. Mestastop's work is crucial as they venture into uncharted territories to combat the complexity of cancer metastasis. #CancerResearch #Innovation #FundingNews

Our company introduction video is live! Learn more about MabGenesis and what sets us apart. Watch now. #biotechnology #phagedisplay #innovation #biopharma #healthcare #animalhealthcare #startups #antibody #VHH #antibodytherapeutics #antibodydiscovery #membraneprotein #GPCR #cancer #autoimmunediseases #inflammatorydiseases

We are delighted to announce the successful USD $25M first close of our Series B financing, and to welcome our new investor Bristol Myers Squibb as we continue to advance PTT-4256 into the clinic later this year. This Series B financing consists of a new strategic investment from Bristol Myers Squibb (BMS), as well as support from existing investors including Canaan and Brandon Capital. Proceeds from the raise will be used for the continued development of Pathios’ unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. This investment comes at an exciting inflection point for Pathios as we progress GPR65 inhibitor PTT-4256 towards our first-in-human clinical trial. We'd like to thank the Pathios team and our collaborators for their incredible work, and our investors who continue to believe in our mission to transform cancer outcomes. To find out more, read the full press release here: https://lnkd.in/dp8XmQwX #fundraising #investment #GPR65 #biotech #clinicaltrials #drugdevelopment #immunotherapy #immunooncology